Skip to main content
Explore URMC

menu

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

Basic Study Information

Purpose:
This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).

Location: University of Rochester Medical Center

Study Contact Information

Study Coordinator: Reference Study ID Number: GO39942 www.roche.com/about_roche/roche_worldwide.htm
Phone: 888-662-6728 (U.S. and Canada)
Email: global-roche-genentech-trials@gene.com

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search